Journal
CLINICAL CANCER RESEARCH
Volume 26, Issue 9, Pages 2085-2086Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-20-0387
Keywords
-
Categories
Ask authors/readers for more resources
The impact on survival of steroids and TNF alpha blockade to treat immune-related toxicity from checkpoint blockade with ipilimumab, nivolumab/pembrolizumab, or combined ipilimumab and nivolumab was assessed using data from a large national database. Using steroids was associated with better survival than the use of TNF alpha-blocking antibodies such as infliximab.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available